Gastrointestinal side effects including nausea, vomiting, and diarrhoea are common during dose escalation Potential effects on heart rate and thyroid function require monitoring Retatrutide is not yet MHRA-approved, limiting access to regulated medical supervision Interactions with intense training demands have not been specifically studied Competitive athletes should monitor WADA guidelines regarding GLP-1 medications Individual responses vary significantly, making personal medical supervision essential Key Takeaways Retatrutide's triple receptor mechanism (GLP-1, GIP, glucagon) may offer superior fat loss with better muscle preservation compared to single or dual agonist medications The medication is most applicable during cutting phases for bodybuilders seeking to reduce body fat while maintaining lean mass Adequate protein intake (2.0-2.2g/kg) and resistance training are essential to maximise muscle preservation benefits Retatrutide is not yet approved in the UK, with expected availability potentially in late 2026 or 2027 following Phase 3 trials Individual response varies significantly, and medical supervision is crucial for anyone considering weight loss medications for body composition goals When to Seek Professional Advice While the potential of retatrutide for bodybuilding applications is genuinely interesting, this is not a decision to make without proper medical guidance
The main pathological processes that influence the outcome of ischemic stroke include neuronal death due to ischemia, disruption of the blood-brain barrier (BBB), and a secondary inflammatory response (Okada and Suzuki, 2020)
In: Catania A (ed) Melanocortins: multiple actions and therapeutic potential
Pure collagen
MEDI0382, A GLP-1/Glucagon Receptor Dual Agonist, Meets Safety and Tolerability Endpoints in a Single-Dose, Healthy-Subject, Randomized, Phase 1 Study
/assets/production/practices/3280152d22c7599df4208c7f13bd6f106ba2a939/images/2788238.jpeg)
